News|Videos|November 16, 2023
CD3, CD20 Bispecifics: A New Frontier in DLBCL Treatment
Author(s)Matthew A. Lunning, DO, FACP
Dr. Lunning explores the FDA-approved CD3- and CD20-targeting bispecifics in relapsed/refractory DLBCL, highlighting their potential impact on heavily pretreated patients.
Advertisement
Episodes in this series
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia whose quality of life is impaired even as her platelet count recovers.
Andrew T. Kuykendall, MD, explains the significance of the FDA approval of rusfertide for polycythemia vera.
Insurance hurdles and steep out-of-pocket costs often delay or prevent patients from filling specialty oral blood cancer drugs, even after eventual approvals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
CLL Treatment Enters a New Era of Targeted Combinations
2
Psilocybin-Assisted Therapy Aims at Existential Distress in Lung Cancer
3
AI in Precision Oncology: A Paradigm Shift
4
SurVaxM Improves OS Only in Younger Subgroup in Newly Diagnosed Glioblastoma
5